Modulating effect of liposomal miR-101 on the processes of amyloidogenesis, smell, sleep and neuroinflammation in experimental Alzheimer's disease

Keywords: miR-101, β-amyloid peptide, cytokines, Alzheimer's disease, sense of smell, sleep, liposomes


The current therapy for Alzheimer's disease does not give patients a chance of recovery. Therefore, it is relevant to study the novel factors of influence, in particular microRNA, on the pathogenic mechanisms of amyloidosis. The aim of this work was to determine the effect of miR-101 on early predictors of amyloidosis in experimental Alzheimer's disease in animals. The study was carried out on 25 male rats of 14 months of age. A model of Alzheimer's disease was created by intrahippocampal administration of Aβ40 aggregates to animals. Ten days later, a 10-day course of nasal administration of miR-101 in liposomes was launched. The level of endogenous Aβ42 and cytokines (TNFα, IL-6 and IL-10) was determined in the supernatants of the nerve tissues of the target brain structures (hippocampus, olfactory bulbs, and olfactory tubercles). A neuroethological method of presenting smells of isovaleric acid and peanut butter was used to assess the olfactory system functional state in the experimental rats. In the course of polygraphic registration of the sleep-wakefulness cycle, the representation of wakefulness and individual sleep phases, as well as proportion of incomplete and complete sleep cycles were determined. It was shown that injection of Aβ40 aggregates into the hippocampus simulates an amyloidogenic state in the rat’s hippocampus and olfactory tubercles, but not in the olfactory bulbs. Moreover, a pro-inflammatory state was registered in the hippocampus of the animal brain (an increase in the concentration of pro-inflammatory cytokines TNFα and IL-6), while the cytokine level in the olfactory bulbs and tubercles did not change. When studying the functional state of olfactory analyzers in the rats with Alzheimer's disease, we revealed negative changes in behavioral response to the smell of isovaleric acid and peanut butter. In terms of somnograms, the Aβ40 toxicity caused reduction in the deep slow-wave sleep stage combined with deficiency of the paradoxical sleep phase, and predominance of incomplete sleep cycles. Nasal therapy with miR-101 in liposomes normalized the level of Aβ42 in the hippocampus and olfactory tubercles and decreased the level of proinflammatory cytokines in the hippocampus. MiR-101 prevented olfactory disfunctions in assessing smells of isovaleric acid and peanut butter, increased the ratio of deep slow-wave sleep and paradoxical sleep in the cycle structure and restored proportion of complete sleep cycles in animals. Thus, liposomal miR-101 has an anti-amyloidogenic and anti-inflammatory effect in rats with a model of Alzheimer's disease. It helps to restore the functional state of olfactory analyzer and optimize structural organization of the sleep-wakefulness cycle in sick animals.


Download data is not yet available.

Author Biographies

V. Sokolik, SI "Institute of Neurology, Psychiatry and Narcology of the NAMS of Ukraine"

Akademika Pavlova Str., 46, Kharkiv, Ukraine, 61068,

N. Levicheva, SI "Institute of Neurology, Psychiatry and Narcology of the NAMS of Ukraine"

Akademika Pavlova Str., 46, Kharkiv, Ukraine, 61068,

V. Geiko, SI "Institute of Neurology, Psychiatry and Narcology of the NAMS of Ukraine"

Akademika Pavlova Str., 46, Kharkiv, Ukraine, 61068,

O. Berchenko, SI "Institute of Neurology, Psychiatry and Narcology of the NAMS of Ukraine"

Akademika Pavlova Str., 46, Kharkiv, Ukraine, 61068,

S. Shulga, SI "Institute of Food Biotechnology and Genomics of the NAS of Ukraine"

Оsipovskogo Str., 2A, Кyiv, Ukraine, 04123,


Berchenko O.G. (1982). Experimental study of the daily periodicity of emotional reactions and its changes in conditions of disturbed wakefulness-sleep processes. Thesis for the Degree of the Candidate of Biol. Sciences. Kharkov. 203 p.

Berchenko O.G. (1990). Neurophysiological organization of the wakefulness-sleep cycle in alcoholism of rats formed in different phases of emotional activity. Physiological Journal of the USSR, 76(6), 713–719.

Brai E., Alberi L. (2015). Simple and computer-assisted olfactory testing for mice. J. Vis. Exp., 100, e52944.

Brito L.M., Ribeiro-Dos-Santos Â., Vidal A.F. et al. (2020). Differential expression and miRNA-gene interactions in early and late mild cognitive impairment. Biology (Basel), 9(9), 251.

Buresh J., Petran M., Zakhar I. (1962). Electrophysiological research methods. Moscow: Foreign Literature Publishing House. 466 p.

Dasgupta I., Chatterjee A. (2021). Recent advances in miRNA delivery systems. Methods Protoc., 4(1), 10.

Drummond E., Wisniewski T. (2017). Alzheimer's disease: experimental models and reality. Acta Neuropathol., 133(2), 155-175.

Gao Y., Liu F., Fang L. et al. (2014). Genkwanin inhibits proinflammatory mediators mainly through the regulation of miR-101/MKP-1/MAPK pathway in LPS-activated macrophages. PLoS One, 9(5), e96741.

Hammond S.M. (2015). An overview of microRNAs. Adv. Drug. Deliv. Rev., 87, 3–14.

Hatfield S., Ruohola-Baker H. (2008). MicroRNA and stem cell function. Cell Tissue Res., 331(1), 57–66.

He L., Hannon G.J. (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet., 5, 522–531.

Hebert S.S., Horre K., Nicolai L. et al. (2009). MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. Neurobiol Dis., 33(3), 422–428.

Hoogland P., Van Den Berg R., Huisman E. (2003). Misrouted olfactory fibres and ectopic olfactory glomeruli in normal humans and in Parkinson and Alzheimer patients. Neuropathology and Applied Neurobiology, 29(3), 303–311.

Huang Y., Shen X.J., Zou Q. et al. (2011). Biological functions of microRNAs: a review. J. Physiol. Biochem., 67(1), 129-139.

Iranifar E., Seresht B.M., Momeni F. et al. (2019). Exosomes and microRNAs: new potential therapeutic candidates in Alzheimer disease therapy. J. Cell Physiol., 234(3), 2296–2305.

Kassil V.G. (1993). Ontogenesis of the formation of various forms of higher nervous activity. Russian Journal of Physiology, 79(3), 1–26.

Kolobov V.V., Storozheva Z.I. (2014). Modern pharmacological models of Alzheimer's disease. Annals of Clinical and Experimental Neurology, 8(3), 38–44.

Kou X., Chen D., Chen N. (2020). The regulation of microRNAs in Alzheimer's disease. Front Neurol., 11, 288.

Kovacs T. (2013). The olfactory system in Alzheimer’s disease: pathology, pathophysiology and pathway for therapy. Translational Neuroscience, 4(1), 34–45.

Kutter C., Svoboda P. (2008). Meeting report: miRNA, siRNA, piRNA. Knowns of the unknown. RNA Biology, 5(4), 181–188.

Larson M., Semb H., Winblad B. et al. (1999). Odor identification in normal aging and early Alzheimer’s disease: effects of retrieval support. Neuropsychology, 13(1), 47–53.

Lobzin S.V., Sokolova M.G., Nalkin S.A. (2017). Influence of brain basal cholinergic system dysfunction on the condition of cognitive functions (literature rev.). North-Western State Med. University, 9(4), 53–58.

Long J.M., Lahiri D.K. (2011). MicroRNA-101 downregulates Alzheimer's amyloid-beta precursor protein levels in human cell cultures and is differentially expressed. Biochem. Biophys. Res. Commun., 404(4), 889–895.

Lowry O., Rosebrough N., Farr A., Randall R. (1951). Protein measurement with Folin phenol reagent. J. Biol. Chem., 193(1), 265–275.

Ma T., Sun X., Sun al. (2016). The study of peripheral blood miR-29a/101 in the diagnosis of Alzheimer's disease. Chin. J. Behav. Med. Brain Sci., 11, 1010–1014.

Madaeva I.M., Berdina O.N. (2017). Modern ideas of «slow sleep» and «ram sleep» and their role in pathogenesis of Alzheimer’s disease (review of literature). Acta Biomed. Sci., 2(4), 48–52.

Manckoundia P., Putot A., Mahmoudi R. et al. (2016). Alterations in olfaction during Alzheimer disease, Parkinson disease and Lewy body disease. Journal of Alzheimer’s Disease & Parkinsonism, 6(5), 274.

Manna I., De Benedittis S., Quattrone A. et al. (2020). Exosomal miRNAs as potential diagnostic biomarkers in Alzheimer's disease. Pharmaceuticals (Basel), 13(9), 243.

Melnik S.A. (2007). Endocrine modification of the olfactory sensitivity of male mice. Abstract of the thesis for the Degree of the Candidate of Biol. Sciences. Nizhny Novgorod: UNN. 23 p.

Melnik S.A., Gladysheva O.S., Krylov V.N. (2012). Effect of preliminary exposure to isovaleric acid vapors on the olfactory sensitivity of male house mice. Sensory systems, 26(1), 52–56.

Mukhin V. (2013). Pathogenesis of the basalforebrain cholinergic dysfunction in Аlzheimer's disease. Sechenov Russian Physiological Journal, 99(7), 793–804.

Nag S., Tang F., Yee B.K. (2001). Chronic intracerebroventricular exposure to β-amyloid (1-40) impairs object recognition but does not affect spontaneous locomotor activity or sensorimotor gating in the rat. Exp. Brain Res.,136(1), 93–100.

Pase P., Himali J.J., Grima N.A. et al. (2017). Sleep architecture and the risk of incident dementia in the community. Neurology, 89(12), 1244–1250.

Patel N., Hoang D., Miller N. et al. (2008). MicroRNAs can regulate human APP levels. Mol. Neurodegener., 3, 10.

Pedroso de Lima M.C., Simões S., Pires P. et al. (2001). Cationic lipid-DNA complexes in gene delivery: From biophysics to biological applications. Adv. Drug Deliv. Rev., 47(2–3), 277–294.

Saika R., Sakuma H., Noto D. et al. (2017). MicroRNA-101a regulates microglial morphology and inflammation. J. Neuroinflammation, 14, 109.

Silva M.V.F., Loures C.M.G., Alves L.C.V. et al. (2019). Alzheimer's disease: risk factors and potentially protective measures. J. Biomed. Sci., 26(1), 33.

Shulga S.M. (2014). Obtaining and characteristic of curcumin liposomal form. Biotechnol. Acta, 7(5), 55–61.

Silvestro S., Bramanti P., Mazzon E. (2019). Role of miRNAs in Alzheimer's disease and possible fields of application.Int. J. Mol. Sci., 20(16), 3979.

Sokolik V.V., Berchenko O.G., Shulga S.M. (2017). Comparative analysis of nasal therapy with soluble and liposomal forms of curcumin on rats with Alzheimer’s disease model. Journal of Alzheimer’s Disease & Parkinsonism, 7, 357.

Sokolik V.V., Shulga S.M. (2015). Effect of curcumin liposomal form on angiotensin converting activity, cytokines and cognitive characteristics of the rats with Alzheimer’s disease model. Biotechnol. Acta, 8(6), 48–55.

Stepanichev M.Yu., Ivanov A.D., Lazareva N.A. (2016). Neurodegenerative changes caused by the introduction of a fragment (25-35) of β-amyloid peptide into the hippocampus are associated with the activation of NGF signaling. Bulletin of the Russian State Medical University, 1, 13–18.

Wang C.C., Yuan J.R., Wang C.F. et al. (2016). Anti-inflammatory effects of Phyllanthus emblica L. on benzopyrene-induced precancerous lung lesion by regulating the IL-1β/miR-101/Lin28B signaling pathway. Integr. Cancer Ther., 16(4), 505–515.

Witt M., Galligan R.M., Despinoy J., Segal R. (2009). Olfactory behavioral testing in the adult mouse. J. Vis. Exp., 23, e949.

Wu H.Z., Ong K.L., Seeher K. et al. (2016). Circulating microRNAs as biomarkers of Alzheimer's disease: Asystematic review. J. Alzheimers Dis., 49(3), 755–766.

Zhang Y., Wang Z., Gemeinhart R.A. (2013). Progress in microRNA delivery. J. Control. Release, 172(3), 962–974.

How to Cite
Sokolik, V., Levicheva, N., Geiko, V., Berchenko, O., & Shulga, S. (2021). Modulating effect of liposomal miR-101 on the processes of amyloidogenesis, smell, sleep and neuroinflammation in experimental Alzheimer’s disease. The Journal of V.N.Karazin Kharkiv National University. Series «Biology», 36, 16-27.